S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. It is
not yet known whether interferon alfa is more effective with or without combination
chemotherapy and interleukin-2 for melanoma.
PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or
without combination chemotherapy consisting of cisplatin, vinblastine, and dacarbazine, plus
interleukin-2, in treating patients who have melanoma.
Phase:
Phase 3
Details
Lead Sponsor:
Southwest Oncology Group
Collaborators:
Cancer and Leukemia Group B Children's Oncology Group Eastern Cooperative Oncology Group National Cancer Institute (NCI)